ARIPIPRAZOLE | N211448 | CMG PHARMACEUTICAL CO LTD
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 2 | Not Yet Recruiting | Christiana Franke | 138 | 2026-10-01 → 2028-12-31 | |
| Phase 2 | Not Yet Recruiting | Vigonvita Life Sciences | 500 | 2026-07-31 → 2027-12-31 | |
| Phase 1 | Recruiting | University of California, San Francisco | 25 | 2025-09-30 → 2027-08-30 | |
| Phase 4 | Recruiting | Northwell Health | 180 | 2024-09-04 → 2030-07-30 | |
| Phase 3 | Recruiting | Minerva Neurosciences | 380 | 2026-04-23 → 2028-12 | |
| Phase 4 | Completed | Federal University of Rio Grande do Sul | 20 | 2005-08 → 2008-03 | |
| Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 1,151 | 2004-09-01 → 2006-12-01 | |
| Phase 2 | Completed | Ajay Wasan, MD, Msc | 308 | 2021-03-31 → 2024-12-20 | |
| Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 135 | 2011-07-27 → 2013-11-06 | |
| Phase 1 | Completed | CMG Pharmaceutical Co. Ltd | 36 | 2015-10 → 2016-03 |
Source: ClinicalTrials.gov. Trials matched by ingredient name; data refreshed each weekday and may lag the registry.
39 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Aug 4, 2026 | SUPPL -1 | View Letter (PDF) |
| Apr 28, 2025 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
| Patent # | Expiration | PED | Drug Substance | Drug Product | Use Code | Delist |
|---|---|---|---|---|---|---|
| 9694008 | Aug 7, 2033 | — | — | Yes | — | — |